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Brucella species are the causative agents of one of the most prevalent zoonotic diseases: brucellosis. Infections by Brucella species
cause major economic losses in agriculture, leading to abortions in infected animals and resulting in a severe, although rarely lethal,
debilitating disease in humans. Brucella species persist as intracellular pathogens that manage to eﬀectively evade recognition by the
host’s immune system. Sugar-modified components in the Brucella cell envelope play an important role in their host interaction.
Brucella lipopolysaccharide (LPS), unlike Escherichia coli LPS, does not trigger the host’s innate immune system. Brucella produces
cyclic β-1,2-glucans, which are important for targeting them to their replicative niche in the endoplasmic reticulum within the
host cell. This paper will focus on the role of LPS and cyclic β-1,2-glucans in Brucella-mammalian infections and discuss the use
of mutants, within the biosynthesis pathway of these cell envelope structures, in vaccine development.
1. Introduction
Brucellosis is a disease that can be found in most countries
around the world and is transferred from animals to humans
[1]. With more than 500,000 new cases of human infections
each year, it is the most prevalent zoonotic disease worldwide
[1]. Although brucellosis very rarely leads to the death of
the patient, it is a seriously debilitating disease that presents
with, among other symptoms, fever, fatigue, nausea, and
weight loss [2]. Brucellosis is thought to be underreported
as the symptoms very often are mistaken for a common flu
[2]. However, if not properly treated, brucellosis can become
a chronic and asymptomatic disease that can re-emerge
months after the initial infection [2]. The causative agents
of brucellosis are brucellae, nonmotile, Gram-negative α-
proteobacteria that are facultative intracellular pathogens
[2]. The genus Brucella currently contains ten species, named
primarily after their preferred host organism or symptoms
of the infection: B. melitensis (goats and sheep), B. abortus
(cattle) [3], B. suis (swine, reindeer and rodents) [4], B. canis
(dogs) [5], B. ovis (sheep) [6], B. neomtomae (rodents) [7], B.
microti (voles and red foxes) [8], B. inopinata (unknown) [9],
B. pinnipedialis (seals), and B. ceti (dolphins and porpoises)
[10]. Most human Brucella infections can be traced back
to the three species, B. melitensis, B. suis, and B. abortus
[11]. The isolation of marine mammal Brucella species (B.
pinnipedialis and B. ceti) from human patients, however,
suggests that these species are emerging human pathogens
[10].
Brucellae enter their hosts either through contact with
infected animals and material, such as blood or milk, or
through the aerosol route [12]. Bacteria of the genus Brucella
are highly infectious, and doses as low as 10 to 100 bacteria
are thought to be suﬃcient to cause the human disease
[12]. Brucellae are therefore considered to be targets for the
development of biological weapons and several countries
were suspected of trying to weaponize Brucella species during
the Cold War [12, 13]. The primary host for Brucella abortus
is cattle where it leads to abortions causing significant
economic losses [1]. As humans are not the primary hosts
for brucellae, the most promising strategies to control and
finally eradicate the disease seems to be through rigorous
vaccination of its primary host, and eﬃcient screening
methods that can diﬀerentiate between vaccinated and
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infected animals [1]. However, most countries have not
implemented an eﬃcient program for disease control [1].
Prohibitive factors are most likely the costs involved but
compared to the potential economic losses caused by animal
brucellosis, these costs are negligible [1].
The infection process of Brucella has been subject
to intense research. The preferred cell types infected by
brucellae are phagocytic cells such as macrophages [14]
(Figure 1). Brucellae are taken up into a phagosome, which
is then targeted to the endoplasmic reticulum, the replicative
niche of the Brucella within the host [12, 14]. Evasion of
the immune system of the host organism and targeting of
the bacterium to its replicative niche are of key importance
for the infection process. The bacterial cell envelope is the
major point of interaction between brucellae and the host
and as such, molecules within the bacterial cell envelope
play a significant part in the infection process. This paper
will focus on the role of two brucellae sugar-modified
cell envelope components, lipopolysaccharide (LPS) and
cyclic β-1,2-glucans (CβGs), in host interactions and vaccine
development.
2. Lipopolysaccharide
Brucellae are Gram-negative bacteria and as such their cell
envelope is composed of two membranes (Figure 2). The
outer membrane plays a crucial role in the infection process,
as it is the first point of interaction between the bacterium
and the host. The outer layer of the outer membrane is
composed of LPS, which consists of three key components:
(i) the lipid A, which forms the hydrophobic anchor of the
LPS within the outer membrane, (ii) an inner and outer
core composed of sugar molecules, and (iii) the O-antigen,
a polymerized sugar chain extending into the extracellular
environment (Figure 2). Brucellae occur naturally as smooth
LPS (S-LPS) strains, which contain LPS that is modified with
an O-antigen, and rough LPS (R-LPS) strains, which lack the
O-antigen [15]. This paper will focus on the importance of
Brucella LPS on the host interaction and on how its structure
can influence the infection process.
2.1. Importance of LPS for the Interaction with Host Cells. In
many bacterial infections, LPS is the major molecule that
is recognized by the innate immune system and can trigger
a severe immune response against the invading organism.
The ability of brucellae to produce S-LPS with a complete
O-antigen is crucial for its virulence in humans [2]. B.
melitensis, B. suis, and B. abortus that express a complete
O-antigen are the main species responsible for human
infections [2]. Mutants of these Brucella species lacking the
O-antigen modification are considerably less virulent than
their respective parent strains [15]. Brucella species that are
naturally devoid of the O-antigen modification such as B.
canis and B. ovis have either a low virulence or are avirulent
in humans [2].
LPS is released by Gram-negative bacteria during their
growth and death and is the cause of endotoxic shock in
septic patients [16]. The LPS of Brucella is less toxic than that
of enterobacterial species and therefore plays a major role for
Brucella in the evasion of the host’s immune system and its
survival thereafter [17, 18]. LPS is the major surface antigen
and is recognized by the immune system by the Toll-like
receptor 4 (TLR4)/MD2 complex [19]. This complex binds
the lipid A component of LPS and, by the recruitment of
additional factors, initiates the innate immune response [19].
Although Brucella LPS binds to TLR4, it does not induce
the production of cytokines and antimicrobial peptides
[12]. Brucella LPS is several hundred times less eﬀective at
inducing the innate immunity than E. coli LPS, and this
is thought to be important for Brucella to evade immune
detection and to form a chronic intracellular infection [12,
15]. The LPS O-antigen plays an important role in the
development of an adaptive immune response to pathogenic
bacteria [19] and is the major antigen that is presented by
the MHC II of B-cells [16]. However, Brucella LPS interacts
with MHC II molecules in a way that prevents signaling and
activation of MHC II dependent T-cells [16, 18]. Therefore,
Brucella LPS acts as an important virulence factor and
prevents the initiation of an adaptive immune response. The
modification of Brucella LPS with its O-antigen also seems to
be essential for the entry of the bacterium into the host cells
(Figure 1). Brucella abortus strains having S-LPS enter the
host cell via lipid rafts and thus the compartment in which
they persist acquires lipid raft marker molecules that are
important for the intracellular targeting of the compartment
to the endoplasmic reticulum (Figure 1) [12, 14]. R-LPS
B. abortus mutants do not enter the host cells through
lipid rafts but through normal phagocytosis and are then
targeted to lysosomes (Figure 1) [12, 14]. Therefore, LPS
plays a crucial role for Brucella in evading both innate and
adaptive immunity and in enabling the bacterium to reach
its intracellular niche.
2.2. Structure and Biosynthesis. Brucella only uses glucose as
its carbon source and is therefore equipped with a set of
enzymes to convert glucose into the diﬀerent types of sugar
molecules utilized within the organism (Figures 3 and 4)
[20]. The biosynthesis of the Brucella O-antigen and core
molecule has not yet been fully characterized and much has
been derived from predicted protein functions and homolo-
gies to other microorganisms and from the identification of
R-LPS mutant phenotypes (Figures 3 and 4) [20–24]. These
data have been used to propose the biosynthetic pathway for
the LPS O-antigen and core (Figure 4) [20].
The biosynthesis of the LPS core molecule and O-antigen
is not located in a single region within the B. melitensis
genome [23]. The majority of the O-antigen biosynthesis
is located in the wbk region and an additional set of two
glycosyltransferases in the wbo region on chromosome I
(Figure 3) [23]. The wbk region has a lower G + C content
(44%–49%) than the average G + C content of the entire
B. melitensis genome (56%–58%) and is flanked by several
insertion sequences indicating that it has been acquired by
lateral gene transfer (Figure 3) [22]. The genes involved in the
biosynthesis of the LPS core molecule are distributed on both
Brucella chromosomes [23]. Two enzymes involved in the
provision on mannose for the LPS core molecule are located
on chromosome II whereas a putative glycosyltransferase
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Figure 1: The Brucella-macrophage interaction. The preferred cells
infected by Brucella are macrophages. Brucella strains with smooth
LPS (S-LPS) enter the cell through interaction with lipid rafts and
are then encompassed in a membrane bound compartment called
Brucella containing vacuole (BCV). This vacuole retains some lipid
raft markers, targeting the BCV to the endoplasmic reticulum (ER).
Brucella fuses with the ER, thus acquiring ER markers to avoid
fusion with the lysosome before beginning to replicate. Rough LPS
mutants do not enter the macrophage through lipid rafts and are
rapidly targeted to the lysosome and killed. Mutants in the CβG
biosynthesis pathway (Δcgs and Δcgt) do not fuse with the ER but
are targeted to the lysosome.
involved in core biosynthesis is located on chromosome I
[20, 22–24]. The glycosyltransferase region (man Bcore &
man Ccore) on chromosome II, however, was not acquired
through lateral gene transfer but has evolved in the organism
through a longer period as the G + C content of these genes
is similar to the rest of the Brucella genome [24].
2.2.1. Core Biosynthesis. The sugar core is linked to the
O-antigen (Figure 2) and is composed of glucose, man-
nose, quinovosamine, glucosamine, 3-deoxy-D-manno-2-
octulosonic acid (KDO), and several yet to be identified
sugars residues [15]. As the full biochemical composition of
the core molecule still remains to be determined, it is not yet
possible to propose a biosynthetic pathway for the core sugar
molecule of Brucella LPS. However, several mutants have
been identified, that were defective in the correct synthesis
of the LPS core.
Phosphoglucomutase. Pgm plays a central role in converting
glucose-6-phosphate into glucose-1-phosphate, making it
indispensable for the biosynthesis of many sugar molecules
in brucellae (Figure 4) [25]. The B. abortus B2211 mutant
was created by the insertion of a nonpolar gentamicin
cassette into the pgm gene of B. abortus 2308. A mutation
in pgm causes a pleiotropic eﬀect on the synthesis of oligo-
and polysaccharides as Pgm is required for the production
of ADP-glucose, UDP-glucose, and UDP-galactose, which
themselves serve as sugar donors for later biosynthetic
processes [25]. The B. abortus pgm mutant lacks the O-
antigen, has an increased susceptibility to complement-
mediated lysis relative to its parent strain, and is attenuated
in its survival within a mouse model [26]. It is generally
believed that the loss of the O-antigen makes bacteria more
susceptible to complement-mediated lysis [15]. In addition
to this, it was found to be involved in the biosynthesis of the
LPS core molecule in B. melitensis. Here, the pgm mutant
also lacked the O-antigen, but its LPS migrated lower on
SDS PAGE gels suggesting a core defect (Figure 4) [20]. This
observation is not surprising as glucose was identified to be a
component of the sugar core of Brucella LPS [20, 26].
Phosphomannomutase. Pmm or ManB is encoded by the B.
abortus and B. melitensis pmm and manB genes, respectively,
[24] and is required for the conversion of mannose-6-
phosphate to mannose-1-phosphate [15]. Brucella encodes
two separate phosphomannomutase genes in its genome
(Figure 3). While manB mutants in the wbk region do not
have an impact on the O-antigen and core biosynthesis,
mutants in the manBcore gene lack the O-antigen and are
defective in the LPS core biosynthesis (Figures 3 and 4) [20,
22–24]. The same observation has been made for the manC
genes in the wbk region, which does not seem to influence
either O-antigen or core biosynthesis and the manCcore gene
on chromosome II (Figures 3 and 4) [20, 22–24]. The manC
genes are predicted to encode mannose-1-phosphate guany-
lyltransferases required for nucleotide activated mannose-
1-phosphate provision (Figure 3) [20, 22–24]. It has been
hypothesized that the manBcore and manCcore genes can
provide mannose both for the biosynthesis of the O-antigen
and the core molecule, whereas the manB and manC genes
in the wbk region only provide mannose for the O-antigen
biosynthesis [20, 22–24]. This assumption is reasonable as
the manBcore and manCcore genes have not been acquired
by lateral gene transfer as were the majority of the genes
involved in the O-antigen biosynthesis in the wbk region.
It is therefore possible that manBcore and manCcore have
evolved primarily for the provision of mannose to the core
biosynthesis pathways but can also provide mannose for the
O-antigen polymerization. Conversely, the manB and manC
genes in the wbk region have evolved to provide mannose
for the O-antigen biosynthesis and cannot compensate for
the loss of the manBcore and manCcore genes in the core
biosynthesis.
The wa∗∗ Gene. This gene encodes a putative glycosyl
transferase in the Brucella genome. A mutant in the wa∗∗
gene was isolated from screening a transposon mutant
library for polymyxin-sensitive mutants [24]. Polymyxin is
a cationic peptide that acts by perturbing membranes of
bacteria by binding to LPS and increasing the permeability
of the cell envelope, and mutants aﬀected in their sensitivity
to polymyxin are likely to be aﬀected in the LPS molecule
[27]. The transposon insertion in the wa∗∗ mutant disrupts
a putative glycosyl transferase gene, which is thought to be
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Figure 2: Diagrammatic representation of the Brucella cell envelope. The cell envelope is comprised of an inner membrane, consisting of a
bilayer of phospholipids, and an outer membrane with an inner leaflet of phospholipids and an outer leaflet of lipopolysaccharide (LPS). LPS
consists of three components. The O-antigen faces the extracellular space and it is the component that is recognized by the adaptive immune
response. The O-antigen is connected to a sugar core molecule composed of diﬀerent sugars which have not yet been fully identified. Lipid
A forms the hydrophobic anchor of LPS within the membrane and has a backbone of diaminoglucose, which is acylated with saturated and
hydroxylated fatty acids. Brucella lipid A contains an unusual very-long-chain fatty acid (VLCFA). Cyclic β-1,2-glucans are synthesized by
the inner membrane protein Cgs and then transported to the periplasm by the predicted ABC-transporter Cgt where they are modified with
on average two succinyl residues by a predicted membrane protein Cgm.
involved in the biosynthesis of the LPS core (Figures 3 and
4). The B. abortus wa∗∗ mutant retains full reactivity with
antibodies directed against the outer core epitope but has a
reduced reactivity for antibodies specific for the inner core
epitope, suggesting that wa∗∗ is required for the correct
synthesis of the inner core of the Brucella abortus LPS
(Figures 2 and 3) [24].
2.2.2. O-Antigen Biosynthesis. The O-antigen of B. abortus
is composed of a linear homopolymer that consists of α-
1,2-linked 4,6-dideoxy-4-formamido-α-D-mannopyranosyl
subunits with a chain length between 96 and 100 sub-
units [15, 22]. O-antigen homopolymers, in contrast to
heteropolymers, are synthesized via a Wzy-independent
mechanism and after its assembly at the cytoplasmic face
of the inner membrane onto bactoprenol phosphate, the
complete lipid-linked O-antigen is transported across the
inner membrane using an ATP-binding cassette (ABC)
transporter system [20, 22]. Wzm and Wzt were identified
and predicted to form the transmembrane and ATPase
domain, respectively, of an ABC transporter required for
the translocation of the full length homopolymer O-antigen
from the cytoplasmic to the periplasmic face of the inner
membrane (Figures 3 and 4) [22]. Indeed, the deletion of
wzm/wzt resulted in the accumulation of intracellular O-
antigen further supporting this hypothesis [22]. Mutants
in the biosynthetic pathways involved in the provision of
perosamine or bactoprenol-P-P-NAc-aminosugars encoded
in the wbk and wbo regions on chromosome I are all aﬀected
in the formation of the Brucella O-antigen (Figure 4 blue and
green pathways) [20–22, 24, 28].
2.2.3. Genetic Variation among Brucella Species. A recent
study has analyzed DNA polymorphisms in wbkE, manA,
manB, manC, wbkF, wkdD, wboA, wboB, wa∗∗, and manBcore
genes between diﬀerent naturally smooth and rough Brucella
species [23]. Interestingly, it was found that B. ovis, a strain
producing naturally rough LPS, lacked the wbo region and
the manA gene but was otherwise identical to smooth LPS
strains [23]. B. canis, another naturally rough LPS strain, had
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Figure 3: Genomic organization of O-antigen and core biosynthesis genes. The genes predicted to be involved in the biosynthesis of B.
melitensis LPS O-antigen and core molecule are distributed at four diﬀerent loci throughout the genome. The majority of the genes are
located in the wbk region and the wbo region on chromosome I. Genes involved in the core biosynthesis can be found on chromosome I
(wa∗∗) and chromosome II (manBcore and manCcore). The wbk region contains multiple insertion sequences (ISs) suggesting that this region
was acquired through horizontal gene transfer [22].
a deletion in wbkD and also in wbkF, both required for the
correct O-antigen synthesis [23]. Interestingly, only very little
polymorphisms were found for the manBcore, manCcore, and
wa∗∗ genes involved in the core biosynthesis [23]. This is
in agreement with a conserved structure in the LPS core of
brucellae and also with a long coevolution of the LPS core
biosynthesis genes among brucellae.
2.3. Lipid A. The lipid A backbone of Brucella is composed
of 2,3-diamino-2,3-dideoxy-D-glucose. This sugar backbone
is modified with saturated fatty acids ranging from C16:0 to
C18:0 and hydroxylated fatty acids ranging between 3-OH-
C12:0 to 29-OH-C30:0 [15]. The unusual modification of Bru-
cella LPS with very-long-chain fatty acids (VLCFA) has been
implicated to be of key importance in stabilizing the Brucella
membrane to the conditions encountered within the host.
A B. abortus bacA mutant has a reduction in the VLCFA-
content of its LPS [29] and was defective in its chronic
infection in BALB/c mice [30]. In the phylogenetically related
bacterium, Sinorhizobium meliloti, a bacA mutant was also
defective in forming an interaction with the plant host, alfalfa
[31]. The lipid A of S. meliloti is also modified with a VLCFA
and deletion of the bacA gene resulted in a reduction in
the lipid A VLCFA-content [29, 32]. However, S. meliloti
mutants in the biosynthesis pathway of these lipid A VLCFA
modifications still formed a successful alfalfa interaction but
were substantially reduced in their competitiveness relative
to the parent strain [33, 34]. S. meliloti mutants lacking
the lipid A VLCFA modification also showed defects in
the development of nitrogen-fixing bacteroides [35]. Taken
together, these findings indicate that the modification of lipid
A with VLCFA plays an important role in the interaction
of α-proteobacteria with their hosts. It has been proposed
that the lipid A VLCFA is important for either protecting
bacteria from the conditions encountered within the host
cells, that is, by stabilizing their outer membrane and/or
6 International Journal of Microbiology
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Figure 4: Predicted pathways of LPS O-antigen and core molecule biosynthesis. Brucellae derive all sugars from glucose. Green arrows indicate
the reactions leading to the synthesis of the monomeric O-antigen subunits, which are polymerized onto bactoprenol (pathway indicated in
blue). The complete O-antigen is then transported to the periplasmic face of the inner membrane by the ABC transporter system Wzm/Wzt
and ligated to lipid A molecule by the O-antigen ligase WaaL. Pathways leading to the biosynthesis of the core molecule are indicated in
red. Hexagons indicate whether mutants in the respective genes are aﬀected in the biosynthesis of the O-antigen (OAg) or the sugar core
molecule (Core). Dotted arrows indicate abbreviated pathways involving the defined enzymes.
in subverting the immune or defense response of the host
[29, 32].
3. Cyclic-β-1,2-Glucans
3.1. Biosynthesis. Cyclic β-1,2-glucans (CβGs) are polymers
of 17 to 24 β-1,2-linked cyclic glucose molecules. Brucella
species belong to the same category of α-proteobacteria
as Agrobacterium tumefaciens and S. meliloti, which also
produce CβGs [36]. As in other Rhizobiaceae, the biosyn-
thesis of CβGs in Brucella is catalyzed by a single cyclic
glucan synthase, Cgs (known as NdvB and ChvB in S.
meliloti and A. tumefaciens, respectively) that can facilitate
the four enzymatic reactions: (i) initiation, (ii) elongation,
(iii) phosphorolysis, and (iv) cyclization required for the
synthesis of CβGs [37–42]. Cgs uses UDP-glucose as a sugar
donor and transfers the glucose molecule onto an unknown
amino acid of Cgs, which acts as an intermediate for the
synthesis of CβG (Figure 2). The linear glucan chain is
extended to a final length of 17 to 24 glucose molecules before
it is cyclized [39]. The degree of polymerization of CβGs
is determined by a C-terminal domain of Cgs [43]. After
their synthesis, the CβGs are transported into the periplasm
by an ABC-transporter system involving the Cgt protein,
which contains conserved motifs of ATP-binding proteins
(Figure 2) [44]. In the periplasm, Brucella CβGs are then
modified with on average 2 O-ester-linked succinyl residues
per molecule by a protein called cyclic glucan modifier
(Cgm) (Figure 2) [45].
3.2. Regulation. Based on comparative studies with the
closely related organisms, A. tumefaciens and S. meliloti, it
was hypothesized that CβG expression in Brucella could
be osmo-regulated as was the case for the aforementioned
bacterial species [37]. Gram-negative bacteria accumulate
osmolytes in their periplasm in order to adapt to changes in
the osmolarity of their environment [46]. CβGs biosynthesis
in S. meliloti and A. tumefaciens has been shown to be
involved in the adaptation of these bacterial species to
hypo-osmotic conditions and NdvB and ChvB mutants,
in the cyclic-β-glucan synthases of S. meliloti and A.
tumefaciens, respectively, are unable to produce CβGs when
grown in media with a low osmotic pressure [37]. The
accumulation of cellular CβGs was also inhibited when
grown under high osmotic conditions [46]. Therefore, in-
vivo data suggested that CβG expression is essential for
the adaptation of A. tumefaciens and S. meliloti to low
osmotic pressures and was down-regulated under high
osmotic conditions. However, membrane extracts of S.
meliloti and A. tumefaciens showed no inhibition of CβG
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biosynthesis at high mannitol or sucrose concentrations
(up to 400 mM) suggesting that the high osmolarity itself
was not responsible for the reduced CβG accumulation
in-vivo [37]. When the membranes were incubated with
high NaCl or KCl concentrations (starting from less than
100 mM NaCl or KCl, respectively), the accumulation of
CβGs was significantly reduced when high osmolarity was
achieved by the addition of sodium chloride or potassium
chloride [37]. The intracellular accumulation of potassium
ions followed by glutamate biosynthesis is a major response
of Gram-negative bacteria to osmotic up-shock and the bac-
teria prevent dehydration by the acquisition of compatible
solutes [47]. Hence it is possible that the uptake of KCl
and the production of other osmolytes in-vivo inhibit the
accumulation of CβGs in environments with high osmotic
pressures.
CβG biosynthesis in Brucella species, however, is not
osmo-regulated [38]. B. abortus S19, an attenuated strain
of the virulent strain 2308 and B. ovis REO198, showed no
reduction in cellular CβG accumulation when grown under
high osmotic conditions [38]. B. abortus S19 membrane
extracts were also found not to be inhibited in the biosyn-
thesis of CβGs when exposed to high KCl concentrations
[40]. When the B. abortus cgs gene was introduced in A.
tumefaciens and S. meliloti mutants in the cyclic glucan
synthase genes, chvB and ndvB, respectively, membranes
extracted from these bacterial strains carrying the B. abortus
cgs gene were able to synthesize CβGs even at high KCl
concentrations of 250 to 500 mM KCl [40]. Conversely,
when the A. tumefaciens chvB gene was introduced into a B.
abortus cgs mutant, it restored its ability to produce CβGs
but the complemented strain was unable to incorporate [14C]
glucose when incubated under high potassium glutamate
conditions [40]. Therefore, Brucella cyclic glucan synthase,
in contrast to the Agrobacterium and Sinorhizobium enzymes,
is not inhibited by the acquisition of intracellular osmolytes
in response to osmotic up-shifts. However, it is interesting
to note that, when a B. abortus S19 cgs mutant was
complemented with the A. tumefaciens chvB gene, the in-
vivo acquisition of CβGs was not aﬀected by high osmolarity
[40]. This suggests that an alternate mechanism is present in
Brucella that can protect the enzyme from the inhibition by
osmolytes. Glycine betaine has been shown to protect and
stabilize enzyme function under hyperosmotic conditions,
and the function of A. tumefaciens and S. meliloti membrane
extracts to produce CβGs under these conditions could
partially be recovered by the addition of glycine betaine [40].
In fact, the osmoregulation of CβG production might not be
required in Brucella, which are poorly adapted to survival
outside a host cell and therefore naturally reside within an
iso-osmotic environment.
3.3. Role in Mice Infections. It was shown that, relative
to the parent strain of Brucella abortus 2308 (a virulent
strain) or B. abortus S19 (an attenuated strain used for
vaccination), mutants in the cyclic glucan synthase gene cgs
and in the cyclic glucan transporter gene cgt were recovered
at a decreased amount from the spleens of infected mice
[38, 39, 44]. Mice infected with either the B. abortus 2308
parent strain, cgs or cgt mutant strain, showed no diﬀerence
in the number of colony forming units (CFUs) recovered
from spleens 4 weeks postinfection [44, 48]. However, after
8 weeks, the number of CFUs in the B. abortus 2308 cgt and
cgs mutants was reduced by approximately 10- to 100- fold,
respectively, while levels in mice infected with the parental
and complemented mutant strains stayed the same [44].
The rate at which the bacteria were “cleared” from infected
mice was significantly diﬀerent between the virulent strain
of B. abortus 2308 and the vaccine strain S19 [44]. In the
B. abortus S19 background, the cgs and cgt mutant showed
significant losses of recoverable Brucella relative to the parent
and complemented strain of 100- to 1000- fold, two weeks
postinfection [44]. Eight weeks postinfection, the B. abortus
S19 cgs mutant was virtually cleared from the infected mice
spleens [48]. At this time point, no diﬀerence was observed
in mice infected with the B. abortus 2308 parent and cgs
mutant strains [48]. CβG therefore plays a major role in the
persistence of Brucella within the host environment. It is
noteworthy that, despite being less virulent, the B. abortus
S19 cgs mutant retained its ability to confer protection in
mice against subsequent B. abortus 2308 infections to a
similar degree as the S19 vaccine strain [48].
3.4. Role in Intracellular Replication. The infection process
of Brucella can be grouped into two phases: the invasion
phase (0–8 hours postinfection) during which Brucella enters
the host cells but does not yet replicate, and the replication
phase when Brucella has reached the rough endoplasmic
reticulum and starts to replicate (Figure 1) [48]. In infection
models using HeLa cells, it was shown that B. abortus 2308,
B. abortus S19, and their respective cgs mutants were not
aﬀected during cell invasion as the same number of CFUs was
recovered 4 hours postinfection [48]. However, cgs mutants
in both Brucella strains showed a lower rate of intracellular
replication relative to the respective parent strains suggesting
that CβGs are required for the normal replication of Brucella
within the host cell [48]. This phenotype has also been
described for a mutant in the pgm gene [26]. This is
not surprising, as mentioned earlier (Section 2.2), Pgm is
essential for the provision of UDP-glucose, the sole sugar
donor for CβG biosynthesis [49].
A recent study showed that CβGs have similarities to
cyclodextrins, cyclic oligosaccharides consisting of α-1,4-
linked glucopyranose units [50]. Cyclodextrins contain a
lipophilic cavity, which allows them to extract cholesterol
from membranes [50]. Cholesterols are a major component
of lipid rafts, microdomains on eukaryotic cell membranes,
which have an increased density of sphingolipids and
cholesterol [50]. These lipid rafts are involved in the
selective transport of molecules, can serve as relay stations
for intracellular signaling and play an important role as
attachment sites for toxins and pathogens [50]. Lipid rafts
can also be found intracellularly on phagosomes and have
been proposed to be involved in phagosome maturation.
Therefore, phagosomal lipid rafts present an ideal target for
intracellular pathogens, which could influence intracellular
signaling and/or traﬃcking by modifying phagosomal lipid
raft domains [50].
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Brucellae need to enter the host cell via these lipid raft
domains, in order to establish a successful and persistent
infection (Figure 1). CβGs have been shown to be able to
perturb eukaryotic cell membranes and to extract cholesterol
from lipid rafts, suggesting that they might work in a
similar manner to cyclodextrins [50]. The role of CβGs in
the virulence of B. abortus has been discussed for a long
time The conclusive proof that CβGs, and not pleiotropic
eﬀects originating from the disruption of CβG, are the cause
for the defects in the interaction of Brucella with its host
was shown recently [50]. By adding external CβGs to cell
cultures infected with B. abortus cgs mutant strain, they
were able to restore its ability to replicate within host cells
to the level of the parent strain [50]. Inside the host cell,
Brucella manipulate the phagosome to evade lysosome fusion
and target the Brucella containing vacuole (BCV) to the
endoplasmic reticulum (Figure 1) [50].
CβGs play a crucial role in the process of evading the
fusion with the lysosome and directing the BCV to the
endoplasmic reticulum. The BCV of cells infected with the
B. abortus cgs mutant progressively acquired cathepsin D, a
lysosomal hydrolase, while in cells infected with CβG-treated
B. abortus cgs mutant and the B. abortus parent strain 2308,
the Brucella strains were able to replicate within cathepsin D
negative BCVs (Figure 1) [50]. Similar results were obtained
when monitoring the acquisition of endoplasmic reticulum-
marker proteins such as calreticulin to the BCV and only
BCV with the parent strain and the CβG-treated cgs mutant
strain were able to fuse with the ER (Figure 1) [50]. CβGs
are therefore an important virulence factor in Brucella
infections, enabling the bacteria to modify the lipid raft
domains of the BCV to avoid lysosome fusion and to target
the BCV to the endoplasmic reticulum [50]. CβGs seem to
be important throughout the whole infection process, and
it has been suggested that because of the key role of CβG
it might be crucial for Brucella that CβG biosynthesis is
not osmoregulated and can be expressed at suﬃcient levels
throughout [50].
3.5. Cyclic-β-Glucans in Other α-Proteobacteria. CβGs are
found among many α-proteobacteria and have been deter-
mined to play a crucial role for Rhizobiaceae to interact with
their host [38]. S. meliloti and A. tumefaciens cyclic glucan
synthase mutants in the ndvB and chvB genes, respectively,
were unable to synthesize CβGs and were incapable to
invade their host plants to form nitrogen fixing nodules
or to cause tumor formation, respectively [38, 51]. It
was therefore hypothesized that CβGs play a major role
for the host infection of these bacteria with their hosts.
Cyclic glucan synthase is a large inner membrane enzyme
and A. tumefaciens, and S. meliloti mutants defective in
this enzyme show pleiotropic membrane defects such as
increased sensitivity to antibiotics and detergents and are
nonmotile due to an inability to assemble flagella [48]. An A.
tumefaciens chvB mutant has also been shown to be defective
in the attachment to surfaces as it produced an inactive form
of the protein rhicadhesin [52] and to express lower level of
the VirB10 transmembrane protein that is part of a type IV
secretion system required for the virulence of A. tumefaciens
and Brucella species [53]. Due to these pleiotropic defects
of cyclic glucan synthase mutants, the role of CβGs in the
virulence of these organisms was uncertain.
4. Vaccination Strategies against
Brucella Species
As most brucellosis cases are contracted through contact with
infected animals or their products, eradication strategies
for the disease are mainly focused on eliminating Brucella,
the causative agent of brucellosis in its primary host [12].
Live, attenuated strains and dead Brucella are used for the
vaccination of animals, and this strategy has been employed
successfully in a number of countries to eradicate the disease
[12]. In the following subsections, we will discuss several
mutants that were or are used for the vaccination of animals
against brucellae.
4.1. B. abortus S19. The most commonly used strain to
vaccinate cattle is B. abortus S19 [54] and a derivative of
it has been used in the former USSR as a live vaccine
for humans [55]. However, B. abortus S19 is not entirely
avirulent in humans and cases have been reported in
which veterinarians dealing with the vaccine strain for
the immunization of cattle have become infected [2]. B.
abortus S19 was originally isolated from milk of an infected
animal as a virulent strain, but has become attenuated
by a spontaneous, unknown mutation during laboratory
culturing [56]. Despite being attenuated, it is serologically
indistinguishable from virulent strains and produces S-LPS
[57]. The eﬀectiveness of vaccinations with this strain and
the production of antibodies to it are dependent on the age
of the animal at the vaccination, the dose, and the route
that the vaccine is applied and the prevalence of brucellosis
within the herd [54]. After the animal is vaccinated, it will be
protected from brucellosis for several years, which can then
be extended by revaccination [54]. However, B. abortus S19 is
not completely avirulent for cows and it can cause abortions
in a small percentage (<2.5%) of immunized, pregnant cows
and orchitis in bulls [54, 58]. Therefore, vaccination with
B. abortus S19 is currently limited to female calves between
the age of three to eight months [59]. The B. abortus S19
vaccine strains have also been linked to arthropathy, when
S19 antigen-containing immune complexes were found in
joints of brucellosis free but vaccinated cattle [60]. A recent
study has identified that mutations in 24 genes of B. abortus
S19 relative to B. abortus 2308 that may account for its loss of
virulence [61]. Among these 24 genes, some were encoding
proteins involved in the metabolism of erythritol and lipids
[61].
4.2. B. melitensis Rev.1. B. melitensis Rev.1 is the most
eﬃcient vaccine strain used to immunize sheep and goats
[58]. The strain was derived from a virulent strain that was
developed to be used as a life vaccination strain and was
made dependent on streptomycin for its growth to control it
within the host [62]. However, although this strain conferred
protection in mice against brucellosis, it proved ineﬃcient
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at protecting monkeys and goats [62]. Therefore, a strain
was selected from isolates that were successful at immunizing
mice and guinea pigs that was no longer dependent on
streptomycin and had also lost some of its virulence [62].
B. melitensis Rev.1 is used as a live vaccine and as it retains
some virulence will lead to abortions if used on pregnant
animals [58, 62]. B. melitensis Rev.1 has been reported in
rare cases to be excreted into the milk of lactating animals,
raising concerns about the vaccination strain infecting other
animals and humans [62]. In fact, cases of animal abortions
caused by B. melitensis infections and human brucellosis
have been reported in which B. melitensis strains were
isolated that were identical in their appearance to the Rev.1
vaccination strain but were sensitive to streptomycin [62].
B. melitensis Rev.1 has an S-LPS phenotype and animals
vaccinated with this strain will raise antibodies against the
O-antigen of B. melitensis [58]. This makes distinguishing
between vaccinated and infected animals using serological
laboratory methods virtually impossible [58].
4.3. B. abortus Strain 45/20. B. abortus 45/20 is an R-LPS
mutant that has been obtained after 20 passages of the B.
abortus isolate 45 through guinea pigs [58, 63]. This mutant
strain produces a small amount of O-polysaccharide, which
is polymerized in a diﬀerent way to the wild type strains and
contains a reduced number of sugar units [64]. Although
this strain was able to protect guinea pigs from Brucella
infections, it is not a stable live vaccine and can revert
back into a virulent strain [58]. However, when used in the
vaccination of cattle, it did not cause abortions [58]. As the
mutation causing the R-LPS phenotype of B. abortus 45/20
is unknown [58] and reversion to the S-LPS and virulent
strain can occur, it is not currently used as a vaccine strain
[63].
4.4. B. abortus RB51. B. abortus RB51 is an attenuated
spontaneous R-LPS mutant that was obtained by repeated
passage of B. abortus 2308 on media containing rifampicin
and penicillin [65]. RB51 carries an IS771 insertion in
wboA, a gene encoding a putative glycosyl transferase, and
is thought to have several other unknown mutations [28].
Even though RB51 has a mutation in the wboA gene, its
LPS contains 2.5 times less mannose than that of other
B. abortus wboA mutants [28]. In contrast to 45/20, this
strain was shown to be a stable rough mutant even after
multiple passages through laboratory cultures and through
infected animals [65]. Therefore, it is currently used in
several countries as a vaccine for cattle [66]. RB51 has been
shown to be eﬃcient in protecting mice against brucellosis
but was not eﬀective when tested in sheep [58]. RB51 is
resistant to rifampicin, which is used in the treatment of
human brucellosis [63].
4.5. Advantages and Disadvantages of Vaccination Strategies.
Many other R-LPS Brucella strains are available for vaccine
development (refer to Section 2). However, as the O-antigen
is the most exposed antigen during Brucella infections
the majority of the adaptive immune response is targeted
towards this antigen. Therefore, rough Brucella mutant
strains in general confer a lower degree of protection than
S-LPS strains. Live attenuated strains of Brucella are the
current method of choice for the vaccination of animals
against Brucella infections; however, there is currently no
licensed human vaccine available [55]. The increased level
of protection conferred by attenuated S-LPS strains is
preferable to the lower level obtained by R-LPS Brucella
strains. On the other hand, S-LPS vaccine strains are bound
to cross-react in the diagnostic assay used to determine
Brucella infections [55] and will therefore make it impossible
to distinguish between vaccinated and infected animals [55].
Finding an attenuated Brucella strain that is both eﬀective
in raising a suﬃcient protection from subsequent infections
and that does not interfere with standard diagnostic test
is a challenge for the future, and several candidates have
been determined in screens for Brucella mutants that are
attenuated in their virulence [55].
5. Conclusions
Sugar-modified cell envelope components play a central role
in the interaction of Brucella with their hosts. LPS is a key
mediator that is detected by the innate immune response. It is
therefore not surprising that Brucella LPS is more adapted to
circumvent the activation of the host’s innate immunity. The
unusual structure of Brucella LPS contributes to suppressing
as well as protecting the bacterium from the immune
response of the host. CβGs are important for intracellular
replication, phagosome maturation, lysosome evasion, and
targeting of Brucella containing vacuoles to the endoplasmic
reticulum. This is achieved by modulating lipid raft domains
of the host cell membrane and the membranes of BCVs.
To facilitate this, constitutive expression of CβGs is required
and this could explain the lack of osmo-regulation found in
the biosynthesis of Brucella CβGs. CβGs are produced by
a number of α-proteobacteria that form interactions with
eukaryotic host cells and were found to be essential for host
interactions. This suggests that CβGs are a key factor for
repressing the perception of these diﬀerent bacterial species
by their hosts. This paper highlights the importance of both
the LPS and CβGs for Brucella to persist within eukaryotic
cells. Therefore, sugar-modified cell envelope components
are key virulence factors for Brucella-host infections. Brucella
mutants that are either defective or result in changes to
these sugar-modified components are often attenuated in
their hosts. It will be interesting to determine whether these
mutants can be developed in the future as vaccines to protect
both animals and humans against Brucella infections.
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